Up 630% this year AND profitable! This small ASX healthcare share is glowing

Why has this stock delivered incredible returns this year? Let's find out.

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

EZZ Life Science Holdings Ltd (ASX: EZZ) shares have been among the very best performers on the Australian share market this year.

Since the turn of the year, the small ASX healthcare share has rocketed a massive 630%.

To put that into context, a $1,000 investment in the genomic life science company's shares at the end of last year would be worth $7,300 today.

Why is this ASX healthcare share thumping the market?

Investors have been scrambling to buy EZZ Life Science's shares this year thanks to its impressive performance in FY 2024.

In August, when the ASX healthcare share released its full year results, it reported a 78.9% increase in revenue to $66.4 million, the doubling of its EBITDA to $10.4 million, and a 91.8% increase in net profit after tax to $6.9 million.

A key driver of this was the launch of 21 new EZZ products in FY 2024, bringing its total active product portfolio to 53 SKUs. It also introduced 10 new distribution channels and expanded networks across key platforms including Douyin, Tmall Global, Kuaishou, Aubay and O'Mall.

EZZ Life Science has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), children's health, and weight management.

Among its products are hair growth sprays and shampoos, eucalyptus stem cell and peptide eyelash and brow serums, and hair masks.

Further revenue growth expected

The ASX healthcare share's chairman, Glenn Cross, was pleased with the year and expects further revenue growth in FY 2025. He said:

We are delighted with our performance In FY24. We have delivered a strong set of financial results as we continued to execute on our growth strategy. We have significantly expanded EZZ's product range and grown our distribution channels in key markets. China has been a strong growth market for the Company this year and we expect it to continue following the strategic relationships we announced during the last quarter of FY24.

While economic conditions are expected to remain challenging given the ongoing cost of living pressures for consumers, EZZ's experienced management team are confident in their ability to deliver continued revenue growth and margin expansion, while driving efficiencies within the business. Our expansion into the US market in FY25 along with our strong balance sheet, which enables us to consider value-accretive growth opportunities, provide confidence that we'll deliver further revenue growth in FY25.

With a market capitalisation of approximately $150 million, EZZ Life Science's shares are now trading at approximately 22x earnings.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Healthcare Shares

Should you buy CSL shares after recent weakness?

Does the dip present a buying opportunity?

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares up 25% in 2 days as Chemist Warehouse merger looks set

The deal continues to create tailwinds for Sigma shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

500 million reasons why ResMed shares are charging higher today

This growing company has big plans and is forecasting strong growth through to the end of the decade.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on

These companies have developed new drugs to treat vision loss and erectile dysfunction.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Guess which ASX 200 healthcare stock is up 12% on big Chemist Warehouse news

Investors appear to believe this news could be a sign that the deal will go ahead.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Can the CSL share price push back above $300?

The biotech last traded there on September 9.

Read more »